TCRTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Alaunos Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026
$3.13+0.50 (+19.01%)
Close on Oct 19, 2026
- Market cap
- $7.61M
- P/E (TTM)
- –
- Dividend yield
- –
Alaunos Therapeutics statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Pharmaceutical Preparations companies for comparison
Valuation
| Measure | Alaunos Therapeutics | Industry median |
|---|---|---|
| Market Cap | $7.95M | $166.30M |
| Enterprise Value | $7.83M | $88.19M |
| PS Ratio | 2650.57 | 3.65 |
| PB Ratio | 12.20 | 2.03 |
| P/TBV Ratio | 12.20 | 2.29 |
Enterprise value
| Measure | Alaunos Therapeutics | Industry median |
|---|---|---|
| EV / Sales | 2609.23 | 2.51 |
Income (trailing twelve months)
| Measure | Alaunos Therapeutics | Industry median |
|---|---|---|
| Revenue | $3.00K | $58.34M |
| Operating Income | -$4.06M | -$21.40M |
| Net Income | -$4.01M | -$22.46M |
| EBITDA | -$4.06M | -$16.91M |
| EPS (Diluted) | -$1.95 | -$0.83 |
Margins
| Measure | Alaunos Therapeutics | Industry median |
|---|---|---|
| Operating Margin | -135267.0% | -44.0% |
| Profit Margin | -133667.0% | -40.2% |
| EBITDA Margin | -135267.0% | -30.2% |
Returns
| Measure | Alaunos Therapeutics | Industry median |
|---|---|---|
| Return on Equity (ROE) | -185.9% | -53.2% |
| Return on Assets (ROA) | -128.3% | -40.9% |
| Return on Invested Capital (ROIC) | -489.4% | -32.4% |
| Return on Capital Employed (ROCE) | -622.4% | -38.1% |
Growth
| Measure | Alaunos Therapeutics | Industry median |
|---|---|---|
| Revenue Growth (YoY) | -50.0% | 5.96% |
| Revenue Growth (3Y CAGR) | -88.0% | 2.25% |
Balance sheet
| Measure | Alaunos Therapeutics | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $124.00K | $61.43M |
| Net Cash (Debt) | $124.00K | $15.35M |
| Net Cash Per Share | $0.05 | $0.66 |
| Equity (Book Value) | $652.00K | $49.09M |
| Book Value Per Share | $0.26 | $1.37 |
| Tangible Book Value | $652.00K | $23.52M |
| Working Capital | -$198.00K | $76.81M |
Financial position
| Measure | Alaunos Therapeutics | Industry median |
|---|---|---|
| Current Ratio | 0.77 | 3.34 |
| Quick Ratio | 0.14 | 2.44 |
Cash flow (trailing twelve months)
| Measure | Alaunos Therapeutics | Industry median |
|---|---|---|
| Operating Cash Flow | -$2.73M | -$12.35M |
Efficiency
| Measure | Alaunos Therapeutics | Industry median |
|---|---|---|
| Asset Turnover | 0.00 | 0.39 |
| Revenue Per Employee | $3.00K | $404.87K |
| Profits Per Employee | -$4.01M | -$703.34K |
| Employee Count | 1 | 74 |
Dividends and yields
| Measure | Alaunos Therapeutics | Industry median |
|---|---|---|
| Earnings Yield | -50.4% | -23.3% |
Shares
| Measure | Alaunos Therapeutics | Industry median |
|---|---|---|
| Shares Outstanding | 2,540,480 | 58,127,000 |
| Shares Change (YoY) | 37.2% | 10.9% |
| Shares Change (QoQ) | 4.53% | 0.54% |
| Float | 835,477 | 49,136,700 |
| Shares Held by Insiders | 67.1% | 11.6% |
| Shares Held by Institutions | 3.56% | 59.4% |
Scores
| Measure | Alaunos Therapeutics | Industry median |
|---|---|---|
| Altman Z-Score | -859.15 | -0.22 |
| Piotroski F-Score | 3 | 4 |
Calculated by StockData from Alaunos Therapeutics's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.